SIGNIFICANCE: Heterotrimeric G proteins are quintessential mediators of intercellular communication. Defining the molecular mechanisms by which this widespread machinery is regulated is of paramount importance because it impacts a vast range of physiological processes and diseases. This is well exemplified by the ongoing research interest in G protein-coupled receptors (GPCRs), the canonical activators of heterotrimeric G proteins and the targets for >30% of marketed drugs. A much less studied aspect of heterotrimeric G protein regulation, but with far-reaching implications, is their ?non-canonical? activation by proteins that are not GPCRs. Among these non-GPCR activators, proteins containing an evolutionarily conserved G?-Binding-and- Activating (GBA) motif, namely ?GBA proteins?, have emerged a key new players in the control of G protein signaling in health and disease. GIV and DAPLE are the prototype members of this family of G protein regulators and both of them are mutated in neurodevelopmental disorders in humans that result in brain birth defects. DAPLE is mutated in non-syndromic congenital hydrocephalus (NSCH) whereas GIV is mutated in Progressive Encephalopathy with edema, Hypsarrhythmia, and Optic atrophy (PEHO)-like syndrome. The cellular and molecular alterations that cause these diseases are poorly understood. BACKGROUND AND GOALS: One of our long-term goals to date has been to identify and characterize a family of cytoplasmic proteins with a GBA motif that activates G protein signaling. Like GPCRs, they have Guanine-nucleotide Exchange Factor (GEF) activity in vitro. Within this context, our goal here is to understand mechanistically how this in vitro GEF activity relates to activation of G proteins and G protein-dependent signaling in living cells, and to establish the importance of this mechanism in vivo. SYNOPSIS OF AIMS: We will (1) dissect how GIV and DAPLE, the two prototype GBAs, affect G protein signaling in cells by using novel chemogenetic platforms and G protein activity biosensors, (2) define how their function is regulated by extrinsic cues by using cell biological assays and novel optogenetic tools, and (3) characterize their impact on neurodevelopment by using animal models. INNOVATION AND IMPACT: Overall, we anticipate that this project will advance the field of heterotrimeric G protein signaling by providing detailed mechanistic insights into a poorly understood aspect of their regulation that impacts human health, and by generating a suite of chemogenetic, optogenetic and biosensor tools to directly manipulate and detect heterotrimeric G protein activity with unprecedented accuracy. The conceptual and technological innovations arising from the successful completion of this project would have a long lasting impact in the field of signal transduction.
Heterotrimeric G proteins mediate the action of many neurotransmitters, hormones and pharmacological agents involved in normal physiology, disease or therapy. Here we propose studies to investigate the mechanisms by which a new type of G protein regulators influences human disease. The most direct, but not exclusive, disease implications are in neurodevelopmental disorders such as hydrocephalus or PEHO-like syndrome.
